BioSpace News Archive

CCRM (Colorado Center for Reproductive Medicine), a global pioneer in fertility science, research and advancement, shared new research on endometrial receptivity testing at the American Society for Reproductive Medicine (ASRM) Scientific Congress and Expo that can help predict the optimal window for embryo transfer following in vitro fertilization (IVF).

Medicare Advantage plans in 63 cities will be recognized for exceptional value in the design of their medical and Part D prescription drug benefits available effective January 1.

Significant Investment to Accelerate Cancer Research Creates First Commercial Single Source for Combined FFPE Acquisition, FFPE RNA Isolation and Long-Read Sequencing

A Phoenix-based technology expert and a behavioral health advocate have joined forces to bridge the gap between in-patient care and long-term sobriety.

One size does not fit all, but the same mindfulness and resilience interventions are often applied generically across distinct behavioral health conditions. Vanderbilt University Medical Center researchers, in collaboration with eMindful,

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has closed its previously-announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company.

The A&R Preliminary Prospectus and Registration Statement are subject to completion and amendment.

After lunch, Dr. Rod Moline and Mr. Joe Williams with the Texas Department of State Health Services (DSHS) will be discussing HB1325 and the role of DSHS with respect to the regulation of consumable hemp product labeling and retailer registration

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediatric Disease (RPD) designation from the U.S. Food and Drug Administration (FDA) for sepofarsen for the treatment of Leber’s congenital amaurosis 10 (LCA10), the most common cause of blindness due to genetic disease in children.

Conference’s key themes include emerging regulations for serialization and traceability, challenges for different stakeholders of the life science industry, the role of GS1 standards and best-in-class practices